A carregar...
Publicação
Catalent´s tumble: is it time to cash out
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 4.78 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
The following paper represents an Equity Research report on
Catalent Inc. The below section is the second part of a two-part
series and focuses on the CDMO market, and a relative valuation
of Catalent. The aim of this part is to provide an in-depth analysis
the pharmaceutical CDMO market, its competitive environment
and key market players to facilitate the final relative valuation
using comparable companies and comparable transactions. The
market analysis includes an overview of the key drivers of the
overall healthcare market, the underlying biologics and pharma
and consumer health market, and our expectations of future
projections of those. Lastly, a final implied share price based on
relative valuation methods is derived. Further, an analysis of the
ESG performance and further risk factors of Catalent’s operations
is explored.
Descrição
Palavras-chave
Valuation Healthcare Cdmo Equity research. Catalent